Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Albert W Garofalo. (2008) Patents targeting γ-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004 – 2008. Expert Opinion on Therapeutic Patents 18:7, pages 693-703.
Read now
Read now
Alistair J Stewart, Anthony Fox, Bruce H Morimoto & Illana Gozes. (2007) Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opinion on Investigational Drugs 16:8, pages 1183-1196.
Read now
Read now
Dirk Beher & Samuel L Graham. (2005) Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease. Expert Opinion on Investigational Drugs 14:11, pages 1385-1409.
Read now
Read now
Articles from other publishers (13)
Sonali Mehendale Munj & Pooja Bhagwan Patil. (2023) Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimer’s:
A Review. Current Topics in Medicinal Chemistry 23:2, pages 77-97.
Crossref
Crossref
Lei Zhang, Laigao Chen, Jason K. Dutra, Elizabeth M. Beck, Sangram Nag, Akihiro Takano, Nahid Amini, Ryosuke Arakawa, Michael A. Brodney, Leanne M. Buzon, Shawn D. Doran, Lorraine F. Lanyon, Timothy J. McCarthy, Kelly R. Bales, Charles E. Nolan, Brian T. O’Neill, Klaas Schildknegt, Christer Halldin & Anabella Villalobos. (2018) Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain. Journal of Medicinal Chemistry 61:8, pages 3296-3308.
Crossref
Crossref
A. J. LarnerA. J. Larner. 2018. Dementia in Clinical Practice: A Neurological Perspective. Dementia in Clinical Practice: A Neurological Perspective
297
329
.
A. Hall & A.I. Velter. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
280
325
.
A. J. LarnerA. J. Larner. 2014. Dementia in Clinical Practice: A Neurological Perspective. Dementia in Clinical Practice: A Neurological Perspective
323
366
.
A.J. LarnerA. J. Larner. 2012. Dementia in Clinical Practice: A Neurological Perspective. Dementia in Clinical Practice: A Neurological Perspective
193
225
.
Anthony F. Kreft, Robert Martone & Alexander Porte. (2009) Recent Advances in the Identification of γ-Secretase Inhibitors To Clinically Test the Aβ Oligomer Hypothesis of Alzheimer’s Disease. Journal of Medicinal Chemistry 52:20, pages 6169-6188.
Crossref
Crossref
Romano Silvestri. (2008) Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Medicinal Research Reviews 29:2, pages 295-338.
Crossref
Crossref
Wen-Lian Wu & Lili Zhang. (2009) γ-secretase inhibitors for the treatment of Alzheimer's disease. Drug Development Research 70:2, pages 94-100.
Crossref
Crossref
A. J. Larner. 2009. Neuropsychological Neurology. Neuropsychological Neurology
39
89
.
Antony J. Davies, Jeremy P. Scott, Brian C. Bishop, Karel M. J. Brands, Sarah E. Brewer, Jimmy O. DaSilva, Peter G. Dormer, Ulf-H. Dolling, Andrew D. Gibb, Deborah C. Hammond, David R. Lieberman, Michael Palucki & Joseph F. Payack. (2007) A Novel Crystallization-Induced Diastereomeric Transformation Based on a Reversible Carbon−Sulfur Bond Formation. Application to the Synthesis of a γ-Secretase Inhibitor. The Journal of Organic Chemistry 72:13, pages 4864-4871.
Crossref
Crossref
Jeremy P. Scott, David R. Lieberman, Olivier M. Beureux, Karel M. J. Brands, Antony J. Davies, Andrew W. Gibson, Deborah C. Hammond, Chris J. McWilliams, Gavin W. Stewart, Robert D. Wilson & Ulf-H. Dolling. (2007) A Practical Synthesis of a γ-Secretase Inhibitor. The Journal of Organic Chemistry 72:11, pages 4149-4155.
Crossref
Crossref
A. J. Larner & M. Doran. (2005) Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene. Journal of Neurology 253:2, pages 139-158.
Crossref
Crossref